Biognosys AG

27 articles about Biognosys AG

• Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

  4/4/2024

  Biognosys and Alamar Biosciences, Inc. are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.

• Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts

  1/23/2024

  Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced the operational readiness of its new proteomics facility in Massachusetts.

• Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

  1/4/2023

  New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics.

• Biognosys Launches New Version of Spectronaut® at HUPO International Proteomics Congress

  12/5/2022

  Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, will launch Spectronaut 17 at the HUPO 2022 World Congress in Cancun, Mexico.

• Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference

  5/26/2022

  Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced the company is attending the American Society for Mass Spectrometry (ASMS) Annual Conference.

• Biognosys Announces Appointment of Beat Lüthi, Ph.D., as independent Board Director

  5/19/2022

  The appointment will support Biognosys’ transformation to a leading provider of protein insights for the development of new breakthrough treatments.

• Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

  4/11/2022

  Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.

• Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022

  3/31/2022

  Biognosys announced today the details of its presence at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held April 8-13, 2022.

• Biognosys Partners with Kymera Therapeutics in Precision Proteomics Biomarkers

  3/15/2022

  Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.

• Biognosys Launches Expanded Suite of Proteomics Platforms to Support Drug Research and Development

  3/3/2022

  Biognosys announced the launch of its expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early stage discovery to clinical settings.

• Biognosys Announces GLP Certification of Its Proteomics Facility by the Swiss Health Authorities

  1/13/2022

  Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced that it has obtained Good Laboratory Practice certification from Swiss health authorities for preclinical studies.

• Biognosys Expands Co-Marketing Agreement with Global Life Science Leader to Advance Proteomics

  12/14/2021

  Biognosys, and Thermo Fisher Scientific, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.

• Biognosys Launches Next-Generation Blood Biomarker Discovery Solution

  11/9/2021

  Biognosys, a leader in proteomics solutions for drug discovery and development, announces the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service.

• Indivumed and Biognosys Extend Strategic Partnership

  10/26/2021

  The Partnership Will Combine Each Company’s Capabilities in Omics Research to Provide Biopharma Customers with Immunopeptidomics Insights for Drug Discovery

• Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference

  10/21/2021

  Biognosys today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry Conference.

• Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine

  10/12/2021

  Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces that it is supporting Cancer Scout as Proteomics provider.

• Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-generation Proteomics

  9/14/2021

  Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.

• Biognosys Announces New Release of Spectronaut™

  6/15/2021

  Biognosys, a leader in next-generation proteomics solutions for life sciences research and development, announced the launch of Spectronaut 15.

• Biognosys Announces Strategic Agreement with Siemens Healthineers

  4/13/2021

  Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California.

• Biognosys announces Nature Communications publication in collaboration with ETH Zurich, Bayer, and BASF

  9/1/2020

  The publication demonstrates the utility of Limited Proteolysis for drug target identification